<DOC>
	<DOCNO>NCT02762981</DOCNO>
	<brief_summary>The purpose study assess safety combination CORT125134 , novel glucocorticoid receptor ( GR ) antagonist , nab-paclitaxel patient solid tumor determine preliminary efficacy combination CORT125134 nab-paclitaxel patient solid tumor . The structure study single arm , non-randomized , open-label , multicenter trial control group . The study conduct approximately 8 site approximately 82 evaluable patient .</brief_summary>
	<brief_title>Study Evaluate CORT125134 Combination With Nab-paclitaxel Patients With Solid Tumors</brief_title>
	<detailed_description>This study conduct two part : Part 1 , dose escalation phase , Maximum Tolerated Dose ( MTD ) Development Regimen determine 42 patient advanced metastatic solid tumor . Treatment administer 28-day cycle , exception first cycle , lead-in 7 day dose CORT125134 . CORT125134 administer orally ( PO ) daily 28 day . Nab-paclitaxel administer intravenously ( IV ) day 1 , 8 15 . Part 2 , dose expansion phase preliminary estimate efficacy make expansion group approximately 20 patient . Enrollment Part 2 study ( dose expansion ) occur development regimen determine .</detailed_description>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients advance metastatic solid tumor disease progression treatment available therapy nabpaclitaxel treatment appropriate . Measurable evaluable disease . Up 3 prior chemotherapeutics regimen advance set . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . For Part 2 Only : Platinumresistant ovarian cancer , Triple Negative Breast Cancer measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 least 1 lesion opinion Investigator appropriate treat nabpaclitaxel . Systemic , inhale prescription strength topical corticosteroid within 21 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CORT125134</keyword>
	<keyword>nabpaclitaxel</keyword>
	<keyword>Triple-Negative Breast Cancer</keyword>
	<keyword>Ovarian Epithelial Cancer</keyword>
	<keyword>GR Antagonist</keyword>
	<keyword>Glucocorticoid Receptor Antagonist</keyword>
</DOC>